Control is not the same as survival
For decades, clinicians managing type 1 diabetes have understood that tighter glucose control saves lives, yet the scale of that truth remained elusive. A six-year nationwide study from South Korea has now given that intuition its most rigorous confirmation: patients who wore continuous glucose monitors were 62 percent less likely to die, and dramatically less likely to suffer the cascade of complications—ketoacidosis, kidney failure, cardiovascular disease—that quietly erode the lives of those living with this condition. The findings, drawn from real-world insurance records rather than controlled trials, carry the particular weight of lived experience, and they arrive at a moment when health systems everywhere are deciding who deserves access to these devices.
- Type 1 diabetes demands constant metabolic vigilance, and for millions of patients without real-time glucose data, the margin for error is dangerously thin.
- A Samsung Medical Center team analyzing nearly 21,000 patients—adults and children alike—found that continuous glucose monitor users faced risks of death and major complications that were cut by more than half across every category measured.
- The 72 percent drop in cardiovascular risk and 57 percent reduction in end-stage kidney disease are not incremental gains; they represent the difference between a life interrupted by organ failure and one that continues unbroken.
- Children showed parallel protection, with CGM use cutting ketoacidosis risk by 56 percent and severe hypoglycemia by 52 percent—findings that challenge any policy leaving pediatric patients without device access.
- Researchers attribute part of the effect to structured education programs bundled with CGM use in Korea's home-care initiative, signaling that the technology alone is necessary but not sufficient.
- South Korea's existing insurance reimbursement policy for CGM now has large-scale real-world validation behind it, and the principal investigators are calling for expanded coverage paired with stronger educational support.
Researchers at Samsung Medical Center have produced what may be the most consequential real-world evidence yet on continuous glucose monitoring: a nationwide analysis of South Korean health insurance records showing that CGM use cuts mortality among type 1 diabetes patients by 62 percent over a six-year period.
The adult study followed nearly 17,000 patients on intensive insulin therapy between 2019 and 2022, splitting them evenly between CGM users and non-users. The outcome differences were not subtle. CGM users experienced 60 percent fewer cases of diabetic ketoacidosis, 57 percent less end-stage kidney disease, and 72 percent lower cardiovascular disease risk. Hospitalizations and emergency visits tied to these conditions fell in parallel. When researchers examined individual patients before and after they adopted CGM, severe hypoglycemia episodes dropped by 61.5 percent—a finding that a simple group comparison had obscured.
A parallel pediatric study of 3,765 patients under 19 confirmed the pattern. Young CGM users faced 56 percent lower ketoacidosis risk and 52 percent lower severe hypoglycemia risk than peers without monitors. Before-and-after analysis showed even steeper reductions: 64 percent fewer ketoacidosis incidents and 57 percent fewer severe low blood sugar episodes after CGM adoption.
The strength of these findings lies partly in their origin. National health insurance claims data reflects ordinary patients in ordinary circumstances, not the curated populations of clinical trials—making the results harder for policymakers to dismiss. Professor Kim Ji-yoon noted that Korea's structured diabetes education programs, bundled with CGM use through a home-care initiative, likely amplified the benefits, underscoring that the device is most powerful when patients are trained to act on what it tells them.
Both studies were published in high-impact peer-reviewed journals, and the research team concluded that the evidence validates Korea's existing CGM reimbursement policy. Principal investigator Professor Kim Jae-hyun called for expanding that coverage while deepening educational support—a prescription that, if followed, could extend these life-altering benefits to a broader population of patients for whom every glucose reading is a decision point.
A team of researchers at Samsung Medical Center has documented something that diabetes specialists have long suspected but never proven at this scale: continuous glucose monitoring devices save lives. The finding comes from a nationwide analysis of South Korean health insurance records spanning six years, and it is substantial enough to reshape how doctors think about managing type 1 diabetes.
The study examined nearly 17,000 adults with type 1 diabetes who were receiving intensive insulin therapy—at least three injections of rapid-acting insulin daily—between 2019 and 2022. Half used continuous glucose monitors; half did not. When the researchers, led by Professors Kim Jae-hyeon and Kim Ji-yoon of Samsung Medical Center's Department of Endocrinology and Metabolism, compared outcomes between the two groups, the differences were striking. Patients wearing the monitors had a 62 percent lower risk of dying from any cause during the study period. They experienced 60 percent fewer cases of diabetic ketoacidosis, a life-threatening condition where the body produces dangerous levels of acids. Their risk of end-stage kidney disease dropped by 57 percent. Cardiovascular disease risk fell by 72 percent.
These are not marginal improvements. They represent the difference between a patient spending a night in the emergency room and going home safely, between needing dialysis and keeping their kidneys functional, between a heart attack and a normal life. The monitors also reduced hospitalizations and emergency visits related to diabetic ketoacidosis by 60 percent and cardiovascular events by 50 percent. When researchers looked specifically at severe low blood sugar episodes—a separate and immediate danger—they found no statistical difference between the two groups overall. But when they examined what happened to individual CGM users before and after they started using the device, severe hypoglycemia incidents dropped by 61.5 percent.
The research team did not stop with adults. They conducted a parallel study of 3,765 children and adolescents under 19 years old, of whom 2,313 used continuous glucose monitors. The pediatric findings mirrored the adult results. Young CGM users had a 56 percent lower risk of diabetic ketoacidosis and a 52 percent lower risk of severe hypoglycemia than their peers without monitors. Before-and-after analysis showed that CGM use reduced ketoacidosis incidents by 64 percent and severe low blood sugar episodes by 57 percent in children.
What makes these findings particularly significant is the source of the data. The researchers analyzed claims submitted to South Korea's National Health Insurance Service, meaning they were looking at real-world outcomes for actual patients, not carefully controlled trial participants. This is the kind of evidence that insurance companies and health ministries pay attention to. Professor Kim Ji-yoon noted that the benefits may have been amplified by structured diabetes education programs that accompanied CGM use in Korea's home-based care pilot initiative. The implication is clear: the devices work better when patients understand how to use them.
The adult study was published in Diabetologia, the official journal of the European Association for the Study of Diabetes, with an impact factor of 10.2. The pediatric findings appeared in Diabetes & Metabolism Journal, the official publication of the Korean Diabetes Association. Both journals carry weight in the global medical community. The research team concluded that their findings validate South Korea's decision to reimburse CGM costs through national health insurance, particularly when paired with education. Professor Kim Jae-hyun, the principal investigator, suggested that expanding insurance coverage while strengthening educational support could push outcomes even further. For patients living with type 1 diabetes—a condition that demands constant vigilance and carries the constant threat of life-altering complications—the message is straightforward: access to continuous glucose monitoring, combined with proper training, can mean the difference between a managed life and a life interrupted by emergencies.
Citas Notables
CGM use is associated not only with improved glycemic control but also with lower risks of acute complications requiring emergency care, chronic complications such as end-stage kidney disease and cardiovascular disease, and even mortality.— Professor Kim Ji-yoon, Samsung Medical Center
CGM is an important tool for reducing mortality and preventing complications in the management of type 1 diabetes. Expanding insurance coverage while strengthening structured diabetes education could further improve patients' long-term outcomes.— Professor Kim Jae-hyun, principal investigator
La Conversación del Hearth Otra perspectiva de la historia
Why does this study matter when we already knew CGM improved blood sugar control?
Because control is not the same as survival. Doctors have known for years that CGM helps patients see their glucose patterns in real time. What was missing was proof that this actually prevented the complications that kill people—kidney failure, heart disease, the acute crises that send you to the hospital at 3 a.m.
The 62 percent mortality reduction is striking. Is that number reliable?
It comes from analyzing insurance claims for nearly 17,000 patients over years, not a small trial. You're looking at what actually happened to real people in a real health system. That's harder to dismiss than a controlled study, though it also means you can't isolate causation the way you could in a lab.
What about the children? Did they benefit equally?
The patterns were similar—56 percent lower ketoacidosis risk, 52 percent lower severe low blood sugar—but the absolute numbers were smaller because children have fewer complications overall. Still, preventing a 10-year-old from going into diabetic ketoacidosis is preventing something that could damage their brain or kill them.
The study mentions structured education. How much of the benefit comes from the device itself versus the teaching?
That's the honest question. The researchers acknowledge that education probably amplified the effect. A CGM is a tool; it only helps if you know what the numbers mean and how to respond. That's why the researchers emphasized that expanding coverage without education would miss the point.
What happens next? Does this change policy?
In Korea, it already has—the government reimburses CGM for patients on intensive insulin therapy. The researchers are essentially saying: this policy works, and it could work better if you expanded it and invested more in teaching patients how to use it. That's a concrete recommendation that health systems can act on.